ArticlePLOS global public health2026
Effect of the COVID-19 pandemic on drug-resistant tuberculosis treatment outcomes at a national referral hospital in Sierra Leone, 2017 to 2022: A retrospective cohort study.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sierra Leone is one of the 30 high TB burden countries in the world, with an incidence rate in 2023 of 273 per 100,000 population. Despite progress in case notification and treatment coverage, around 5,000 cases of TB in Sierra Leone are missing each year. The COVID-19 pandemic has further compounded these challenges. We highlight its effect on drug-resistant TB treatment outcomes. We conducted a retrospective cohort study of drug-resistant TB cases using national data from January 2017 to December 2022. Data was analyzed using STATA. Descriptive analysis summarized demographic, clinical characteristics and treatment outcomes. Logistic regression examined the association between time-period and outcomes, adjusting for age, gender, nutritional status, HIV status and regimen. Of 701 patients, 383 (54.6%) were registered pre-COVID-19, 228 (32.5%) during, and 92 (13.1%) post-COVID-19. Pre-treatment TB cases reduced from 359 (92.5%) in the pre-COVID-19 period to 80 (30.9%) in the COVID-19 period. New treatment cases increased from 29 (7.5%) to 159 (61.4%) during COVID-19. Treatment completion decreased from 74.7% pre-COVID-19 to 63.3% during and 68.5% post-COVID-19). Malnourished patients had higher odds of success (aOR: 1.482, 95% CI: 1.007-2.183), while those on short regimen had lower odds (aOR: 0.51, 95% CI: 0.321-0.810). We observed a decline in drug-resistant TB treatment success rate during COVID-19, which was primarily influenced by concurrent shifts in treatment protocols and underlying secular trends. The pandemic itself did not emerge as an independent determinant of poor treatment outcomes, highlighting the resilience of the TB care system. Nonetheless, the pandemic had significant indirect consequences, including worsening rates of malnutrition and HIV co-infection. These trends point to deeper systemic vulnerabilities, such as weak social protection mechanisms, increased food insecurity, and disruptions in HIV service delivery, all of which contributed to delay in diagnosis and compromised treatment adherence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.